Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

5 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Trop-2 cleavage by ADAM10 is an activator switch for cancer growth and metastasis.
Trerotola M, Guerra E, Ali Z, Aloisi AL, Ceci M, Simeone P, Acciarito A, Zanna P, Vacca G, D'Amore A, Boujnah K, Garbo V, Moschella A, Lattanzio R, Alberti S. Trerotola M, et al. Among authors: boujnah k. Neoplasia. 2021 Apr;23(4):415-428. doi: 10.1016/j.neo.2021.03.006. Epub 2021 Apr 8. Neoplasia. 2021. PMID: 33839455 Free PMC article.
Trop-2 induces ADAM10-mediated cleavage of E-cadherin and drives EMT-less metastasis in colon cancer.
Guerra E, Trerotola M, Relli V, Lattanzio R, Tripaldi R, Vacca G, Ceci M, Boujnah K, Garbo V, Moschella A, Zappacosta R, Simeone P, de Lange R, Weidle UH, Rotelli MT, Picciariello A, Depalo R, Querzoli P, Pedriali M, Bianchini E, Angelucci D, Pizzicannella G, Di Loreto C, Piantelli M, Antolini L, Sun XF, Altomare DF, Alberti S. Guerra E, et al. Among authors: boujnah k. Neoplasia. 2021 Sep;23(9):898-911. doi: 10.1016/j.neo.2021.07.002. Epub 2021 Jul 25. Neoplasia. 2021. PMID: 34320447 Free PMC article.
3D-Informed Targeting of the Trop-2 Signal-Activation Site Drives Selective Cancer Vulnerability.
Guerra E, Trerotola M, Relli V, Lattanzio R, Tripaldi R, Ceci M, Boujnah K, Pantalone L, Sacchetti A, Havas KM, Simeone P, Travali N, Querzoli P, Pedriali M, Roversi P, Iezzi M, Tinari N, Antolini L, Alberti S. Guerra E, et al. Among authors: boujnah k. Mol Cancer Ther. 2023 Jun 1;22(6):790-804. doi: 10.1158/1535-7163.MCT-22-0352. Mol Cancer Ther. 2023. PMID: 36921314